SCYNEXIS starts Phase 1 trial of SCY-770 AMPK activator in ADPKD program
PUBT · 4d ago
Share
Listen to the news
- SCYNEXIS launched a Phase 1 study of SCY-770, an oral AMPK activator being developed for autosomal dominant polycystic kidney disease.
- Results have not been presented; topline Phase 1 data are expected in Q3 2026.
- The trial aims to guide dose selection for a Phase 2 proof-of-concept study targeted to start in Q4 2026.
- SCY-770 has FDA orphan drug designation for ADPKD, supporting a rare-disease development strategy.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SCYNEXIS Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606300800PRIMZONEFULLFEED9754152) on June 30, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved